Tag: fingolimod

"Siempre tenemos la esperanza de que las cosas mejoren en el futuro y de que, algún día, consigamos encontrar una cura definitiva para la esclerosis múltiple. Hasta entonces, tenemos que seguir las investigaciones más recientes".

Efforts to improve access to MS treatments continue

New research suggests the rate of brain atrophy, or brain shrinkage, may be an important indicator of disease progression in MS.

Fingolimod has been approved by the US Food and Drug Administration (FDA) as a treatment for children and young people aged 10 years and older with relapsing MS

A phase II trial shows safety and efficacy of amiselimod

Researchers find that suddenly stopping fingolimod may lead to severe worsening of symptoms in MS

Swedish study favours rituximab over fingolimod for those at risk of progressive multifocal leukoencephalopathy

French researchers compare oral and injectable drugs for relapsing-remitting MS

An international study looks at the safety and efficacy of a drug similar to fingolimod

A new trial has failed to show Fingolimod has any effect of in primary-progressive MS

Switching from natalizumab to an alternative drug may prevent disease reactivation

Study shows that switching to natalizumab is more effective than switching to fingolimod

Fingolimod is effective in reducing relapses and brain volume loss

The results suggest that primary progressive and relapsing forms of MS have different underlying mechanisms

Underweight women and patients with low baseline lymphocyte counts should be monitored more closely